Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonraybio CoTPE:6955 +1.11%66 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus rates TPE:6955 with a GF Score™ of 66/100 and a GF Value™ of NT$151.96 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 315 Medical Devices & Instruments companies, Bonraybio Co ranks worse than 317460% on this metric.
Bonraybio Co's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Bonraybio Co's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 6 years, Bonraybio Co's highest Yield on Cost was 1.20. The lowest was 0.11. And the median was 0.76.
TPE:6955's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.43 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Bonraybio Co (TPE:6955) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Bonraybio Co 5-Year Yield-on-Cost % Related Terms
TPE:6955 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Bonraybio Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Bonraybio Co is calculated as
Bonraybio Co (TPE:6955) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bonraybio Co and its competitors. Over the past decade, Bonraybio Co's 5-Year Yield-on-Cost % has ranged from 0.11 to 1.20. According to the industry distribution chart, Bonraybio Co ranks #999999 out of 315 companies in the Medical Devices & Instruments industry.
Is Bonraybio Co's 5-Year Yield-on-Cost % too high?
Bonraybio Co's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.20. Based on the distribution chart, Bonraybio Co ranks #999999 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bonraybio Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #999999 out of 315 companies for 5-Year Yield-on-Cost %. This places Bonraybio Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Historically, Bonraybio Co's own 5-Year Yield-on-Cost % has ranged from 0.11 to 1.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$151.96, compared to a current price of NT$100.00 — trading 34.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Bonraybio Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$100.00 is trading 34.2% below its estimated GF Value™ of NT$151.96.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
5-Year Yield-on-Cost %: 0.00
GF Value™: NT$151.96 vs. price of NT$100.00 (34.2% below fair value)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
66GF Score
Get the complete analysis for TPE:6955
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
